Hookipa Pharma Inc (HOOK)

NASDAQ
1.450
-0.020(-1.36%)
After Hours
1.420
-0.030(-2.069%)
- Real-time Data
  • Volume:
    90,152
  • Day's Range:
    1.450 - 1.509
  • 52 wk Range:
    1.230 - 6.490

HOOK Overview

Prev. Close
1.47
Day's Range
1.45-1.509
Revenue
11.97M
Open
1.47
52 wk Range
1.23-6.49
EPS
-1.65
Volume
90,152
Market Cap
79.32M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
231,345
P/E Ratio
-0.799
Beta
0.765
1-Year Change
-76.5%
Shares Outstanding
54,704,528
Next Earnings Date
Nov 16, 2022
What is your sentiment on Hookipa Pharma?
or
Market is currently closed. Voting is open during market hours.

Hookipa Pharma Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Hookipa Pharma Inc Analysis

Hookipa Pharma Inc Company Profile

Hookipa Pharma Inc Company Profile

Employees
123

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company’s preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.

Read More

Analyst Price Target

Average6.750 (+365.52% Upside)
High16
Low2
Price1.45
No. of Analysts8
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellSellStrong Sell
Technical IndicatorsStrong SellStrong SellSellStrong BuyStrong Sell
SummaryStrong SellStrong SellStrong SellNeutralStrong Sell
  • Bought half a dozen shares on a whim afte reading profile. 20 days later up 15%. Not bad.
    0